Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2.

Therapeutic immunology - 1 Feb 1995

Rubin J T, Day R, Duquesnoy R, Simonis B, Adams S, Lee J, Lotze M T

Abstract excerpt

AIM: The risk of developing melanoma, the natural history of this disease, and the response to therapy with biological reagents may be determined, in part, by a patient's human leukocyte antigen (HLA) phenotype. In order to study this, the relationship between HLA type and clinical response to therapy with interleukin-2 (IL-2) was evaluated. METHODS: We retrospectively determined the HLA phenotype of 82 patients...

Topics

Alleles
Gene Frequency
HLA-DQ Antigens
Humans
Interleukin-2
Melanoma
Phenotype
Prognosis
Retrospective Studies

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 7553066

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-7553066-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2.PMID 7553066Read ↗

HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.Semantic proximity Read ↗

Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?Semantic proximity Read ↗

HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2).Semantic proximity Read ↗

Association of HLA phenotype with response to active specific immunotherapy of melanoma.Semantic proximity Read ↗

HLA-B8 association with late-stage melanoma--an immunological lesson?Semantic proximity Read ↗

Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer Stage I or II.Semantic proximity Read ↗

HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma.Semantic proximity Read ↗

HLA-DQB1*0301 association with increased cutaneous melanoma risk.Semantic proximity Read ↗

Phenotypic heterogeneity of HLA products on human melanoma cells.Semantic proximity Read ↗

HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.